Navigation Links
Clexane(R)/Lovenox(R) Approved in Japan
Date:1/28/2008

atment option for millions of patients at risk of VTE(2). In arterial thrombosis, Clexane(R) / Lovenox(R) has demonstrated its effectiveness in preventing, in conjunction with other treatments, the ischaemic complications of unstable angina and myocardial infarction and is also recommended by international guidelines(2).

About Clexane(R) / Lovenox(R)

The no. 1 selling low-molecular weight heparin in the world, Clexane(R) / Lovenox(R), is a unique chemical entity in a class of antithrombotic agents known as low-molecular weight heparins (LMWH).

Its clinical applications are linked to its antithrombotic properties. It is used to inhibit clot formation in venous and arterial vessels to prevent potential acute or chronic complications of venous or arterial thrombosis.

The recommended dose regimen of Clexane(R) in Japan is 20 mg b.i.d subcutaneous and has been established with the results of Japanese clinical trials.

Enoxaparin sodium is known by the brand name Lovenox(R) or Clexane(R) or Klexane(R) and its labelling may vary country to country.

About venous thromboembolism (VTE)

Venous thromboembolism is a general term used to describe the formation of a blood clot (thrombus) that blocks a vein. This may occur in any part of the venous system, but the most common manifestations are deep-vein thrombosis (DVT), usually in the leg, and pulmonary embolism (PE). PE is a potentially life-threatening complication of DVT; anyone who experiences DVT is at risk of a PE, which occurs when part or all of a blood clot in a deep vein breaks away from where it originally formed and travels through the venous circulation, eventually becoming lodged in the lungs. This blocks the flow of blood in the lungs and is often fatal.

The total annual burden of non-fatal symptomatic VTE in the European Union, which included DVT and PE, is estimated to exceed 1.5 million events, including more than 500,000 deaths(3). This represents more than
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
2. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
3. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
6. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
7. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
8. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
9. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... DES MOINES, Iowa (PRWEB) July 23, 2014 ... will join the business as vice president of Agricultural ... from Mendel Biotechnology where he served most recently as ... brings extensive biotechnology and business leadership in the seed ... DuPont Pioneer,” said Paul E. Schickler , president ...
(Date:7/23/2014)... 2014  Sofinnova Ventures, a Menlo Park ... of Sofinnova Venture Partners IX, L.P. at the hard ... initial fund target of $425 million. Sofinnova ... Consistent with recent funds, SVP IX will provide capital ... along with select investments in earlier stage opportunities. Investments ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Adult ... transplant therapies are biological, but not magical. ... seem to treat them as if they were ... as unsanctioned studies that constitute “stem cell tourism,” ... an approach to developing new regenerative medicine therapies. ...
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST) ... a new design for an atomic clock that ... a microcomb. , The microcomb clock, featured on ... new journal Optica ,* is the first ... its accurate conversion of optical frequencies to lower ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Sofinnova Raises $500 Million Biotech Venture Fund 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 2The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 3The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 4The Adult Stem Cell Technology Center, LLC Continues to Develop Technologies for Homologous Adult Stem Cell Therapies and Drug Development 5'Comb on a chip' powers new NIST/Caltech atomic clock design 2
... industrial design at the Milwaukee Institute of Art and ... will assist people with spinal damage with their toileting activities. ... are paralyzed from the neck or the waist down can ... moving their bowels. Since they have no sensation in the ...
... , Milwaukee OnCourse Technologies , a ... have signed a term sheet to sell two subsidiaries to ... are involved in CAD/CAM technology: TekSoft creates the ... and distributor of related products. The deal is expected to ...
... researchers have put enough monitoring equipment on a bicycle to ... soap bubbles, and found losing sleep makes you hungry. Interested? ... ,Put a GPS monitor on a bicycle, add devices ... and rhythm created by their peddling, record it all at ...
Cached Biology Technology:This wheelchair will save lives 2This wheelchair will save lives 3Tech Digest: OnCourse, Menasha, Fiserv, Rockwell 2A week in UW research: fusion, racing and sleep 2A week in UW research: fusion, racing and sleep 3
(Date:7/23/2014)... -- The potential for clinical use of induced ... strategies has previously been hindered by the risk ... tumors. The ability to use etoposide treatment to ... of heart disease, specifically acute myocardial infarction, is ... and Development , a peer-reviewed journal from Mary ...
(Date:7/23/2014)... mollusks, starfish, and corals have in common? Aside ... calcifiersorganisms that use calcium from their environment to ... and protection. , The July issue of ... Biological Laboratory, addresses the challenges faced by these ... atmospheric carbon dioxide rises, the world,s oceans are ...
(Date:7/23/2014)... -- BCC Research ( www.bccresearch.com ... AND TECHNOLOGIES FOR SENSORS , the global market for ... nearly $154.4 billion by 2020, with a five-year compound ... and level sensors segment is moving at a significant ... , Sensors have become indispensable to many ...
Breaking Biology News(10 mins):Calcification in changing oceans explored in special issue of The Biological Bulletin 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 2Global Market for Sensors to Reach Nearly $154.4 Billion in 2020; Image Sensors Moving at 11.7% 3
... six-month study by Iowa State University researchers had indicated ... isoflavones, lessened lumbar spine bone loss in midlife, perimenopausal ... of those same researchers does not show a bone-sparing ... except for a modest effect at the femoral (hip) ...
... 5, 2010) New research from the Hood Center for Children ... time sheds light on the significant potential negative impact that ... children. The study, which appears in the current edition ... the "brand placements" for food, beverage, and food retail establishments ...
... ( T. gondii ) is considered as one of the ... wide range of intermediate hosts, including all mammals and birds. ... and 20% in the world are chronically infected. ... now accepting applications for its Investigative Workshop, Modeling Toxoplasma ...
Cached Biology News:Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 2Multicenter study finds little effect of soy isoflavones on bone loss in postmenopausal women 3New study examines the impact on children of food product placements in the movies 2New study examines the impact on children of food product placements in the movies 3Modeling Toxoplasma focus of workshop 2
Human Carnosine Dipeptidase 1 Affinity Purified PAb...
... Interactions between P-selectin and P-selectin glycoprotein ligand-1 ... on the lumenal surface of endothelial cells ... the primary role of PSGL-1 in mediating ... been well documented.MAB4092 completely blocks recognition of ...
Mouse Anti-Human MCAF-(MCP-1)...
Mouse VEGF R1/Flt-1 Phycoerythrin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Biology Products: